Technology
Health
Biotechnology

Cue Biopharma

$8.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.39 (4.92%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cue Biopharma and other stocks, options, ETFs, and crypto commission-free!

About

Cue Biopharma, Inc. Common Stock, also called Cue Biopharma, is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Read More Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Employees
46
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
172.71M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
96.67K
High Today
$8.41
Low Today
$8.00
Open Price
$8.00
Volume
21.96K
52 Week High
$14.66
52 Week Low
$4.16

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2018 IPO
US
North America

News

Yahoo FinanceMay 9

Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference

Overview and Update on the Immuno-STAT Platform for Selective Targeting of Tumor-specific T cells CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will participate in a panel discussion en...

13
Yahoo FinanceApr 29

If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Cue Biopharma, Inc. (NASDAQ:CUE) share price has gained some 74% in the last three months. But that doesn't change the reality of under-performance over the last twelve months. In fact, the price has declined 25% in a year, falling short of the returns you could get by investing in an index fund. Check out our latest analysis for Cue Biophar...

60
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.